Page 1

MDxHealth NEWS RELEASE - REGULATED INFORMATION 21 APRIL 2021 , 07:00 A.M. CET MDxHealth Provides Q1-2021 Business Update - - IRVINE , CA , and HERSTAL , BELGIUM – April 21 , 2021 – MDxHealth SA ( Euronext : MDXH.BR ) , a commercial- stage innovative molecular diagnostics company , today provided a business update for the first quarter ended March 31 , 2021 . Michael McGarrity , CEO of MDxHealth , commented : “ We believe our results support our positive view forward as we come through the effects of the pandemic on our business and patient flow in our U.S. market . We remain confident that the fundamentals we have driven into our operating discipline and commercial execution will continue to be demonstrated and reflected in our results going forward . " Our sequential growth in unit volume for ConfirmMDx for the third quarter in a row , coupled with 23 % sequential growth in revenue is clear evidence of our recovery from the pandemic - induced decline in patient flow and screenings for prostate cancer , as previously noted , to be down roughly 50 % . As expected , our ConfirmMDx results reflect an opening of patient flow and we expect SelectMDX to follow as restrictions ease , vaccinations roll out , and our inclusion in the NCCN guidelines continues to take hold . All of these leading indicators point to a turn to sustainable growth and we look forward to providing additional guidance with our mid - year results in August . " Highlights for the first quarter ended March 31 , 2021 • • Successful completion of a EUR 25 million ( approximately $ 30.4 million ) capital increase in January 2021 , with broad support from U.S. and European investors including continued support from our Reference shareholders , MVM , Valiance and BioVest Total revenue of $ 5.1 million , down 14 % from $ 5.9 million in Q1-2020 , and up 23 % sequentially from Q4-2020 • Sequential growth of 6 % in ConfirmMDx units compared to Q4-2020 • Cash and cash equivalents of $ 38.2 million as of March 31 , 2021 Summary of billable test volume by product Products Confirm MDx SelectMDx Subsequent events • 2021 3,913 3,529 Quarter Ended March 31 , 2020 % Change 4,532 4,383 ( 14 ) % ( 26 ) % On April 19 , 2021 , MDxHealth and Kreos Capital executed an amendment to the 2019 loan facility , extending the interest - only period from 18 months to 27 months . As a result of this amendment , repayment of principal has been extended from May 2021 to February 2022. As part of the amendment , the Company agreed to increase the end - of - loan fee by an additional € 67,500 ( approx . $ 80,000 ) as well as to provide for an additional € 202,500 of the € 9 million loan to be convertible into shares of MDxHealth at a 25 % premium to the 30 - day volume weighted average price 10 days prior to signing the amendment . If exercised , this amount will be reduced from the principal amount due under the loan agreement .